Randomized trial shows semaglutide enhances metabolic health in schizophrenia, implying potential treatment benefits.
Weekly injections of semaglutide over 26 weeks were more effective than matching placebo in improving glycemic control and weight outcomes in patients with schizophrenia who received clozapine or olanzapine, a randomized trial has found. Participants receiving semaglutide did not experience a disproportionate number of adverse events. Study results were published online Dec. 3, 2025 in JAMA Psychiatry .
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: